Alcon Inc. - Registered Shares
ALC
Market Cap$47.36B
Close$
Earnings Call Q4 2024
February 26, 2025 - AI Summary
Strong Financial Performance in 2024: Alcon reported sales of $9.8 billion, representing a 6% growth year-over-year (YOY). Core diluted EPS increased by 16% to $3.05, and the company generated a record $1.6 billion in free cash flow, indicating strong operational health and profitability.
Product Pipeline and Growth Opportunities: The company revealed an extensive product pipeline with key upcoming launches including UNITY VCS (a phacovit device) and PanOptix Pro (a PCIOL lens). Expectations for a strong product roll-out in the second half of 2025 are high, with revenue anticipated to accelerate as these products penetrate the market.
2025 Revenue and Growth Guidance: Alcon forecasts full-year revenue for 2025 between $10.2 billion and $10.4 billion, representing a constant currency growth rate of 6% to 8%. This guidance reflects anticipated challenges from competitive trialing and pricing dynamics in the U.S. market, particularly in the ATIOL segment, alongside strengths in international markets.
Exclusive for Stockcircle Pro members
Sign up
$27.84
70.1% downside
Current Fair Value
70.1% downsideOvervalued by 70.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $47.36 Billion |
|---|---|
| Enterprise Value | $50.90 Billion |
| Dividend Yield | $0.26441 (0.276146214099217%) |
| Earnings per Share | $2.06 |
| Beta | 0.75 |
| Outstanding Shares | 494,400,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 46.5 |
|---|---|
| PEG | -138.85 |
| Price to Sales | 4.66 |
| Price to Book Ratio | 2.17 |
| Enterprise Value to Revenue | 5.13 |
| Enterprise Value to EBIT | 35.47 |
| Enterprise Value to Net Income | 49 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Alcon, Inc.
20,000 employees
CEO: David J. Endicott Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the followi...